On a standalone basis, the companys net profit has contracted by 21% to Rs 10.55 crore despite a 2% growth in revenue from operations to Rs 54 crore in Q3 FY22 over Q3 FY21. The companys domestic sales registered a growth of 3% while exports jumped 88% in Q3 FY22.
EBITDA margin in Q3 FY22 was 28.21% as against 38.97% in Q3 FY21. On the account of COVID restrictions during Q3, there was a reduction in the expenses for traveling and conveyance, which has contributed for better margins in that period, the company said.
Hester Biosciences is one of Indias leading animal healthcare companies and is the second largest poultry vaccine manufacturer in the country.
The scrip advanced 3.27% to currently trade at Rs 2468 on the BSE.
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
